Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN27354239
ISRCTN27354239
Completed
未知

A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex versus an oral anti-diabetic in combination with sulfonylurea administered orally for the treatment of type two diabetes

Institut de Recherches Internationales Servier (France)0 sites847 target enrollmentJuly 11, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Institut de Recherches Internationales Servier (France)
Enrollment
847
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

  1. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22723853
Registry
who.int
Start Date
July 11, 2006
End Date
February 1, 2008
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Institut de Recherches Internationales Servier (France)

Eligibility Criteria

Inclusion Criteria

  • •1\. Male or female aged between 35 and 80 years
  • •2\. Body mass index (BMI) between 25 and 45 kg/m2
  • •3\. Treated in monotherapy with sulfonylurea
  • •4\. Presenting type 2 diabetes

Exclusion Criteria

  • •1\. Type 1 diabetes
  • •2\. Known latent autoimmune diabetes in adults

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylurea administered orally for the treatment of type 2 diabetes.Type II DiabetesMedDRA version: 7.0Level: PTClassification code 10012613
EUCTR2005-004798-60-CZI.R.I.S. Institut de Recherches Internationales Servier840
Active, not recruiting
Not Applicable
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylurea administered orally for the treatment of type 2 diabetes.
EUCTR2005-004798-60-DEI.R.I.S. Institut de Recherches Internationales Servier840
Completed
Not Applicable
SWITCH - Sensing With Insulin pump Therapy to Control HbA1cType 1 diabetes mellitusNutritional, Metabolic, Endocrine
ISRCTN09806152Medtronic International Trading Sarl (Switzerland)160
Active, not recruiting
Phase 1
A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., in patients with Chronic Obstructive Pulmonary Disease.COPD (Chronic Obstructive Pulmonary Disease)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPD
EUCTR2009-014410-10-SKChiesi Farmaceutici SpA506
Active, not recruiting
Not Applicable
A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., in patients with Chronic Obstructive Pulmonary Disease.
EUCTR2009-014410-10-DEChiesi Farmaceutici SpA506